CompletedNCT01654601
A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg
Medication studyAges 20–60South KoreaSchizophrenia
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 20 years to 60 years. Other eligibility criteria applied.
- Listed locations
- Choongju and 4 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateJune 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 28
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- South Korea
- Age range
- From 20 Years to 60 Years
- Official registry ID
- NCT01654601
- Official title
Show the full official title
Clinical Trials to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg After a Multi-dose Oral Administration in Schizophrenia Patients
Get this study by email
Recruitment & locations
CompletedChoongju · Iksan · Naju
1 more locations
- Seoul
Questions about this study
Who is behind this study?
The study sponsor is Dong Wha Pharmaceutical Co. Ltd., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including DWCZP and Clozaril.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 20 years to 60 years. Other eligibility criteria applied.
